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 Abstract 
Background. Clozapine remains the only evidence based antipsychotic for treatment 
resistant schizophrenia (TRS). The ability to predict which patients with their first onset of 
schizophrenia would subsequently meet criteria for treatment resistance (TR) could help to 
diminish the severe functional disability which may ensue if TR is not recognised and 
correctly treated. 
Methods. This is a 5 year longitudinal assessment of clinical outcomes in a cohort of 246 
first-episode schizophrenia spectrum patients recruited as part of the NIHR Genetics and 
Psychosis (GAP) study conducted in South London from 2005-2010. We examined the 
relationship between baseline demographic and clinical measures and the emergence of TR. 
TR status was determined from a review of electronic case records. We assessed for 
associations with early, and late onset TR, and non-TR, and differences between those TR 
patients treated with clozapine and those who were not.   
Results. Seventy percent (n=56) of TR patients, and 23% of the total study population 
(n=246) were treatment resistant from illness onset. Those who met criteria TR during the 
first five years of illness were more likely to have an early age of first contact for psychosis 
(<20 years) (OR=2.49, 95%CI 1.25-4.94) compared to those with non-TR. The relationship 
between an early age of first contact (<20 years) and TR was significant in patients of Black 
ethnicity (OR=3.71 95%CI 1.44-9.56); and patients of male gender (OR=3.13 95%CI 1.35-
7.23).  
Conclusions. For the majority of the TR group, antipsychotic treatment resistance is present 
from illness onset, necessitating increased consideration for the earlier use of clozapine. 
Key words. Schizophrenia; treatment-resistant; first-episode psychosis; clozapine; 
longitudinal 
  
Introduction  
Treatment resistant schizophrenia (TRS) is a major cause of disability and functional 
impairment and affects up to 30% of those diagnosed with schizophrenia (Meltzer, 1997). 
Clozapine is the only evidenced based effective medication for TRS. In the UK, it is 
recommended that clozapine be offered to people with schizophrenia whose illness has not 
responded adequately to treatment despite the sequential use of adequate doses of at least 
two different antipsychotic drugs (NICE., 2014). At present it is not possible to predict those 
who will not respond to first line antipsychotic treatments.  
Early identification of patients who require clozapine has the potential to improve clinical 
outcomes and minimize the social and functional disability that results from prolonged 
psychosis (Lewis et al., 2006, Stroup et al., 2016, Wheeler et al., 2009). Previous studies 
investigating risk factors for TR have utilised clozapine prescription rates as a proxy 
measure of TR ((Nielsen et al., 2012b, Schneider et al., 2015, Stroup et al., 2014), however, 
given the underutilisation of clozapine in clinical practice, such studies do not measure all 
people with TR. Although, a few potential risk factors for treatment resistance (TR), such as 
poor premorbid functioning, living in less urban areas, comorbid personality disorder,  longer 
duration of untreated psychosis (DUP), greater severity of negative symptoms, and a 
younger age of illness onset have been suggested (Frank et al., 2015, Martin and Mowry, 
2016, Meltzer, 1997, Ortiz et al., 2013, Schennach et al., 2012, Vanelle et al., 1994, 
Wimberley et al., 2016), the predictive value of specific clinical and demographic factors on 
treatment resistance in first episode schizophrenia has not yet been widely investigated (Lin 
et al., 2008). Further, while there is a large literature investigating predictors of treatment 
response and remission from illness onset (Carbon and Correll, 2014, Menezes et al., 2006), 
TR has not been examined longitudinally as an outcome measure in FEP. 
 Therefore in our study, using a quasi-prospective cohort design, we sought to identify clinical 
and demographic risk factors, noted at first contact for psychosis, which were predictive of 
TR as assessed at the end of the first five years of illness. We explored associations 
between TR and a number of risk predictors, including type and severity of symptoms, 
gender, age at first contact for psychosis, ethnicity, duration of untreated psychosis (DUP) 
and premorbid level of functioning. We looked for differential clinical and social factors 
between those who showed “early-resistant” TR (E-TR) (within six months of first onset of 
schizophrenia with no period of remission from illness onset) and those with “late-resistant” 
TR (L-TR).  We further assessed for differences between those with E-TR and those who 
were not treatment resistant (non-TR), and those with L-TR and those who were non-TR. 
We additionally compared the TR patients treated with clozapine with those who met the 
criteria for the TR but had not received clozapine, in terms of sociodemographic and clinical 
characteristics at the time of first illness onset.  
Methods 
Sample ascertainment  
Participants were recruited as part of the National Institute of Health Research (NIHR) 
Biomedical Research Centre (BRC) Genetics and Psychosis (GAP) study conducted in the 
urban centre of South London, UK. Further details of the study are available in Di Forti et al 
(Di Forti et al., 2013). For the purpose of the present study, only FEP cases who met criteria 
for the following ICD10 diagnoses: F20.0, F25.0, F28.0, F29.0, (referred to as schizophrenia 
spectrum psychosis; there are no cases of schizotypal disorder included) (WHO, 1992) 
validated by administration of the Schedules for Clinical Assessment in Neuropsychiatry 
(WHO, 1994) were included at baseline. All cases had been admitted to psychiatric inpatient 
units or seen by community based mental health teams of the South London and Maudsley 
(SLaM) NHS Foundation Trust, London between December 2005 and October 2010. All 
recruited cases were aged 18-65 and were resident in the study catchment area. The study 
exclusion criteria were evidence of 1) psychotic symptoms precipitated by an organic cause; 
2) evidence of transient psychotic symptoms resulting from acute intoxication as defined by 
ICD-10; 3) moderate or severe learning disabilities as defined by ICD-10; or 4) head injury 
causing clinically significant loss of consciousness. 
Ethics 
The BRC-GAP study was granted ethical approval by the South London and Maudsley and 
Institute of Psychiatry Local Research Ethics Committee (reference number: 05/Q0706/158). 
All cases gave informed written consent after reading a detailed information sheet. 
Data ascertainment at baseline 
Sociodemographic characteristics. Information on sociodemographic characteristics was 
collated using the Medical Research Council (MRC) Socio-demographic Schedule modified 
version (Mallett et al., 2002). Age at first contact with mental health services for psychosis 
was further categorised into four groups based on the results of interquartile analyses (18-
20, 21-25, 26-30, and > 31 years). Ethnicity was self-ascribed using the 16 categories 
employed by the UK Census in 2001 (www.statistics.gov.uk/census 2001). A detailed 
assessment of lifetime patterns of cannabis use and alcohol intake was collated employing 
the Cannabis Experience Questionnaire modified version (Di Forti et al., 2009). 
Clinical assessments. The baseline diagnoses were made from face-to-face interviews and 
mental health records according to ICD-10 criteria (WHO, 1992) utilising the Operational 
Criteria Checklists (OPCRIT) (McGuffin et al., 1991). The OPCRIT system consists of a 90-
item checklist and uses computerised diagnostic algorithms based on published criteria to 
provide a diagnostic category for each subject employing a number of classification systems 
(McGuffin et al., 1991). The degree of psychopathology at first presentation to mental health 
services was measured on the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 
1987). Overall functional disability was assessed using the Global Assessment of 
Functioning (GAF). Duration of untreated psychosis (DUP) was defined as the difference 
between the date of onset of psychotic symptoms to the date of treatment with antipsychotic 
medications (Malla et al., 2006, Singh et al., 2005).  
The Family Interview for Genetic Studies (FIGS; 
https://www.nimhgenetics.org/interviews/figs) and clinical records were used to obtain 
information about patients’ family history of mental health problems. A family history of 
psychosis variable was derived following consensus diagnoses based on the available 
information and referred to the presence or absence of a current or past psychotic disorder 
in at least one first-degree relative.  
Current IQ was estimated using Wechsler Adult Intelligence Scale, version III (WAIS-
III)(Wechsler D, 1997) and pre-morbid IQ was estimated using the Wechsler Test of Adult 
Reading (WTAR) (Wechsler, 2001). Premorbid and current IQ estimates, and the difference 
in IQ estimate between the premorbid and current IQ were compared between the TR and 
non TR groups. 
Tracing patients at follow up  
Approximately five years after first contact for psychosis, a retrospective database search of 
clinical history was carried out using the Electronic Psychiatric Clinical Records (EPCRs) 
database in the South London and Maudsley NHS Foundation Trust (SLaM). The EPCRs 
are the primary clinical records system within the Trust. The EPCRs were searched from the 
time of the FEP for a follow up period of five years in order to complete the data extraction. 
All deaths and emigrations up to and including those that occurred during the final year of 
follow up were identified by a case-tracing procedure with the Office for National Statistics 
(ONS) for England and Wales and the General Register Office (GRO) for Scotland. 
Data at follow up 
At follow-up, extensive information was collated across clinical and social outcome domains, 
from clinical records using the WHO Life Chart Schedule (LCS) extended version(Sartorius 
et al., 1996). The LCS is designed to provide retrospective assessments of the long-term 
course of schizophrenia. Detailed information was collated on medication history including 
the number of antipsychotic medications used prior to commencing clozapine, medication 
initiation/discontinuation dates, antipsychotic dose, medication adherence and the primary 
reason for changing or discontinuing each antipsychotic medication.  
Definitions of treatment resistance (TR) 
Patients were defined as having TR if they had been treated with clozapine at any point 
during the five year follow up period. We also defined cases as treatment resistant if during 
the follow up period they showed little or no symptomatic improvement to two consecutive 
treatments with antipsychotic medications of adequate dose and duration (at least 6 weeks), 
even though they were not commenced on clozapine (NICE., 2014). An adequate daily dose 
of antipsychotic medication was defined according to a daily dose of at least 400mg 
chlorpromazine equivalence (Leucht et al., 2014). We only included as cases those patients, 
who failed to respond, and not those who were intolerant of antipsychotic medications or 
those who self-discontinued medication.  
Those who met the criteria for TR were divided into two subgroups: 1) “early-resistant” 
treatment resistance (E-TR) were those cases who met criteria for TR and who did not 
experience a symptomatic remission from the time of the first presentation and 2) “late-
resistant” treatment resistance (L-TR) were those cases who had experienced a response to 
antipsychotics and attained a symptomatic remission (of at least 6 months duration), but at a 
later stage failed to respond to the ongoing use of non-clozapine antipsychotics, meeting the 
criteria for TR.  
Similar to earlier work conducted in the same geographical region (Morgan et al., 2014, 
Revier et al., 2015) , and in keeping with work from Andreasen et al., (Andreasen et al., 
2005), using information extracted from clinical records, remission was defined as the 
absence of overt psychotic symptoms, including positive or and negative symptoms 
(operationalised as a score of 0 or 1 on rating scale 2 in the SCAN (WHO, 1994); 
0=absence, 1= symptom occurred, but fleeting, 2=symptom definitely present, 3=symptom 
present more or less continuously) for 6 months or longer. This definition of remission was 
not dependent on the presence of non-psychotic symptoms (e.g., depressed mood), nor 
whether the patients were receiving treatment during remission. 
Data Analysis 
Comparisons between the groups were conducted using x2 tests or Fisher’s exact test for 
categorical variables and t-test or Mann-Whitney U test for continuous variables. Penalised 
logistic regression (PLR) was used to analyse the relationship between the predictors for TR 
(Heinze and Schemper, 2002). To explore the moderating effects of gender and ethnicity in 
predicting the risk for TR, we examined whether there were significant interactions between 
these variables and the independent predictors of TR status at follow up. Confounding 
factors were identified through correlation analyses between the primary outcome (i.e. TR vs 
non-TR at five years) and a number of clinical and sociodemographic factors measured at 
baseline and during the follow up period. All variables with p<0.05 were included in the final 
model as confounding factors. Consequently, we adjusted the PLR analyses for the following 
variables: age at first contact for psychosis; living arrangements, and employment status and 
alcohol/substance misuse during the follow up period. All analyses were conducted in 
STATA release 14 (STATACorp LP, USA). 
Results 
Sample characteristics  
At first onset of psychosis, the sample comprised 283 cases with a diagnosis of a 
schizophrenia spectrum psychosis (ICD-10 classification codes: F20.0, F25.0, F28.0, F29.0), 
with an average age of 27.7 (SD=8.6) years. Seventy three percent were admitted to 
hospital at the time of their first presentation with psychosis and at the time of study 
recruitment, with 27% recruited from community based mental health settings.  There were 
no significant differences between those recruited from an inpatient setting and those from a 
community setting in mean total PANSS scores (p=0.35), and mean negative PANSS scores 
(p=0.70) between those recruited from an inpatient setting and those from a community 
setting. Inpatients had significantly increased mean positive PANSS scores compared to 
those recruited from community settings (p=0.02). 
A flow chart depicting how the cases were traced and administrative outcomes is presented 
in Figure 1. Approximately 5 years (meanyears=5.4, SD=2.5; 1,310 persons years) after first 
contact for psychosis, 10 (3.5%) had emigrated, 4 (1.4%) had died, 2 (0.7%) were excluded 
on the basis of lack of sufficient information to trace these patients over time and 21 (7.4%) 
cases we were unable to contact. Those who died were significantly older (Supplementary 
Table 1). 
Core analytic cohort 
We successfully traced 246 (86.7%) of the original cohort. Of these, 67.5% were male and 
60.0% were of Black ethnicity. There were 240 cases with sufficient treatment information 
over the follow up period to determine TR or non-TR status. Eighty one (33.7%) of the cases 
met our criteria for TR and 159 (66.3%) were non-TR. The other six (2.4% of the core 
analytic cohort) cases had not received an adequate trial of antipsychotic to allow it to be 
determined if criteria for TR, or for non-TR was met. 
Comparisons in baseline sociodemographic and clinical characteristics between the TR 
group and non-TR group are presented in Table 1. The TR group had a significantly younger 
age at first contact for FEP (meanyears=25.2, SD=6.4) than the non-TR group 
(meanyears=27.9, SD=8.3) (t(238)=2.57, p=0.01). The median length of DUP for the non-TR 
group was 4 weeks (IQR=1-17) which was not significantly different from the DUP in the TR 
group (median=4.5 weeks, IQR=1-26) (U test=-0.92, p=0.36). Patients with TR did not have 
an increased family history of psychosis compared to patients in the non-TR group (x2=0.10, 
df=1, p=0.75). There was no significant difference between the mean IQ in the TR group 
(mean=92.6 SD=13.0) compared with the non-TR group (mean= 87.5 SD=16.2) (Mann 
Whitney U test=-1.25 p=0.22). The mean premorbid IQ was higher in the TR group 
(mean=92.8 SD=9.6) compared to those in the non-TR group (mean=88.5 SD=11.0), but this 
did not reach statistical significance (Mann Whitney U test=-1.58 p=0.11). There were no 
other significant differences between the groups in terms of other baseline socio-
demographic characteristics. 
[Insert table 1 here] 
Predictors of treatment-resistance (TR) 
Baseline clinical predictors of treatment resistance (TR) at five-year follow up for the whole 
sample and stratified by ethnicity and gender are presented in Table 2. Those patients who 
were defined as treatment resistant were more likely to have an early age of first contact with 
mental health services (<20 years) compared to the non-TR group (OR 2.49, 95% CI 1.25-
4.94). There were significant interactions between age at first contact for psychosis with 
ethnicity (p=0.02) and gender (p=0.002). Therefore, in addition to exploring the impact of age 
at first contact in predicting TR in the cohort, we further stratified the analyses by gender and 
ethnicity. We observed that this relationship between an early age of first contact for 
psychosis (<20 year) and TR was significant in cases of Black ethnicity (OR 3.71, 95% CI 
1.44-9.56) and in male patients (OR 3.13, 95% CI 1.35-7.23) (Table 3). 
[Insert table 2 &3 here] 
“Clozapine” group vs “met criteria” group  
Among those patients who were defined as TR, 38 cases (46.9% of N=81, and 15.4% of 246 
cases with a diagnosis of schizophrenia spectrum psychosis at study recruitment) 
commenced treatment with clozapine; whereas 43 cases (53.1% of N=81) met criteria for 
clozapine but did not commence it. A higher proportion of patients in the clozapine group 
(91%) lived with family members or friends compared to the “met criteria” group (48.0%) 
(x2=6.04, p=0.01). The clozapine group exhibited more severe psychopathology (t(27)=2.49, 
p=0.02) and negative symptoms (U test =2.410, p=0.03) compared to the “met criteria” 
group at first contact for psychosis (Supplementary Table 2).  
The clozapine group had increased negative symptoms (mean 21.7 (SD=9.1) compared to 
the non-TR group (mean 15.4, SD=6.0) (U test=-2.22 p=0.02)  
“Early-resistant” TR (E-TR) vs “late-resistant” TR (L-TR) and vs the non-TR groups 
Among those with TR, 56 (70.0% of 80 with TR) were E-TR and 24 (30.0% of N=80) were L-
TR. The E-TR group expressed more severe psychopathology at baseline (mean total 
PANSS score=69.9, SD=20.4) than the non-TR group (mean total PANSS score=60.9 
SD=16.4) (t(95)=-1.98, p=0.05) (Supplementary Table 3). Cases in the L-TR group were 
significantly younger at the time of first contact for psychosis (meanyears =23.7, SD=5.1) 
compared to the non-TR group (meanyears=27.9, SD=8.3) (t(181)=2.44, p=0.02) 
(Supplementary Table 4).  
A higher proportion of the E-TR group (74% of n=56) were male compared to the L-TR 
group (46%) (x2=6.39, p=0.01). There were no other significant differences between the 
groups in terms of ethnicity, socio-demographic and clinical characteristics at baseline. 
Discussion 
This is the largest study of a first episode schizophrenia spectrum psychosis cohort to 
assess the clinical and demographic risk factors associated with the emergence of treatment 
resistance (TR). TR illness was seen in 34% of patients by five years follow-up. Our principal 
finding was that 70% of the treatment resistant cases did not respond to antipsychotics from 
illness onset.  
An earlier age of first contact for psychosis was strongly associated with TR at five years 
follow up. This finding of an association between a first contact with mental health services 
for psychosis before the age of 20 and TR was most marked for males, and for those of 
black ethnicity. Early onset schizophrenia is associated with worse outcomes compared to 
adult onset schizophrenia(Ropcke and Eggers, 2005, Vyas et al., 2007), and a younger age 
of illness onset has been previously associated with the emergence of treatment resistance 
(Meltzer et al., 1997, Vanelle, 1995), though our study is the first longitudinal study in first 
episode schizophrenia spectrum psychoses to identify this. These findings should alert 
clinicians to be more vigilant in individuals with a first episode of schizophrenia spectrum 
psychosis in late adolescence (age <20) in terms of their response (or lack thereof) to initial 
trials of antipsychotics and to be prepared to use clozapine more promptly when a lack of 
response is evident.  
There was no difference between age of first contact in the TR group between males and 
females, though in the non-TR group, males were younger at the time of first contact. This 
observation, combined with the younger age of schizophrenia onset in those who eventually 
develop a treatment resistant course of illness is compatible with a greater role for 
neurodevelopmental impairment in this subgroup of schizophrenia patients, and a course of 
illness which differs premorbidly from that of non-TR patients. However, we did not find that 
the estimated deterioration in IQ scores, or a family history of psychosis was greater in the 
TR group compared to the non-TR group, and we did not identify that environmental risk 
factors were more prevalent in the non-TR group. These findings do not provide support for 
a neurodevelopmental pre-eminence in the TR group. 
The severity of baseline clinical symptom profiles was not associated with TR over the 
course of the five year follow up. Although, we were unable to identify any associations with 
increased negative symptomatology at first contact and the emergence of TR, they were 
predictive of those who had been treated with clozapine. Further, we found that increased 
severity of psychotic symptoms at baseline was associated with E-TR compared to those 
with non-TR.  
Early resistant and Late resistant TR (E-TR) 
Of the TR group, 70% displayed unremitting symptoms from the time of first antipsychotic 
treatment. The finding that 23% of the total population met the criteria for TR from illness 
onset indicates that this course of illness is not associated with prior antipsychotic use and 
raises the possibility that it may be a distinctive and homogenous schizophrenia subgroup, in 
line with evidence that there are biological differences between treatment resistant and 
treatment responsive schizophrenia (Demjaha et al., 2014, Demjaha et al., 2012). This 
finding mirrors the rate of 20% who displayed ‘chronicity’ from illness outset in a  FEP 
population (Wiersma et al., 1998), though is higher than a previous finding of 10% of FEP 
cases found to have shown no response to antipsychotics at the end of the first year of 
treatment (Robinson et al., 1999). Further, our finding that 70% of the TR group displayed E-
TR, is similar to an earlier study in established schizophrenia, which identified that over half 
of patients with ‘poor outcomes’, remained psychotic from illness onset (Kolakowska et al., 
1985). The high rates of early resistance of those with TR in this population is an important 
finding, which needs to be viewed in relation to the delay in clozapine use which exists in 
clinical practice (Howes et al., 2012), specifically the under use of clozapine within the first 1-
2 years of illness presentation. 
A minority of those with TR (i.e. 30%) initially responded to antipsychotic medications, before 
developing L-TR. One possibility is that the loss of antipsychotic response may be due to the 
emergence of dopamine receptor supersensitivity in these cases. Dopamine supersensitivity 
is postulated to occur due to upregulation of dopamine receptors and neural adaptation 
(Chouinard, 1991, Iyo et al., 2013) and it has been estimated that 50% of TR might be due to 
the emergence of dopamine supersensitivity (Chouinard and Chouinard, 2008). Conversely, 
previous studies have found that over the course of illness, approximately one in six develop 
a lack of antipsychotic response subsequent to relapses (Emsley et al., 2012, Wiersma et 
al., 1998), a lower rate of L-TR than the 30% identified in our study. It may be that there was 
a greater delay in treatment change for patients who relapsed in our naturalistic clinical 
setting, than in the closely monitored setting of the open label study of Emsley et al.,(Emsley 
et al., 2012) in which patients had a treatment initiation at the time of relapse. This delay in 
antipsychotic use, may have contributed to the higher rate of L-TR which we have identified, 
due to the evolving nature of TR in the context of relapse.  
Our findings indicate that two distinct patterns of TR develops in patients, with the majority 
displaying TR from the onset, and a smaller subset of patients developing TR after periods 
of relapse, or with a later emergence of an intrinsic TR with a propensity for poorer outcomes 
and attenuated antipsychotic response overtime. 
Implications for practice 
Increasingly, cases of first episode schizophrenia spectrum disorders in higher-income 
countries are managed within dedicated early intervention and first episode psychosis (FEP) 
services; however delays remain in the initiation of clozapine (Howes et al., 2012). In our 
study, 70% of those with TR would have been most appropriately treated with clozapine at 
an early stage of their presentation, particularly given evidence that early treatment with 
clozapine is effective (Agid et al., 2011), and that worse outcomes are seen with a delayed 
use of clozapine(Nielsen et al., 2012a, Ucok et al., 2015).   There is a need for a greater 
awareness and appreciation within FEP services that early resistance to antipsychotics is a 
not uncommon phenomenon. We would conjecture that on the basis of our findings 
consideration for early and judicious use of clozapine is appropriate.  
Access to clozapine 
Clozapine was commenced in less than half of those with TR over the course of the 5 years 
follow up. Those who were commenced on clozapine in our study, were more likely to exhibit 
more severe psychotic symptoms, and increased negative symptomatology at baseline, 
when compared to those who ‘met-criteria’ for clozapine use, indicating that a more florid 
psychosis is likely a factor in a clinician’s decision for the earlier use of clozapine in TR. 
Perhaps a more significant finding in relation to practice and clozapine initiation, was that 
those started on clozapine were significantly more likely to be living at home with family, 
compared to those  who ’met criteria’ for TR. Perhaps clozapine treatment is restricted for 
some who meet criteria for TR, due to a lack of family support (perceived or otherwise) or 
due to unstable living arrangements. These factors should prompt consideration for the 
provision of more dedicated hospital and community facilities to allow for the successful 
completion of the early stages of clozapine use, with adequate supported accommodation 
provided as required, to enable continued clozapine use. There is some evidence that such 
an approach is effective in increasing access to clozapine (Beck et al., 2014). 
Methodological considerations 
Strengths of this study include the quasi-prospective design which allowed for the follow up 
of first episode schizophrenia spectrum psychosis cases over the first five years of illness. 
We have examined the course of TR in a naturalistic setting, from the time of the first use of 
antipsychotic medication, describing the pattern of TR onset, and identifying robust 
associations with the onset of TR.  
Limitations to our study design include the small population of female patients and the lack 
of a robust measure of medication adherence, which may have affected the association with 
meeting the criteria for TR (McCutcheon et al., 2015). The unsystematic use of clozapine in 
this cohort is a further limitation in our estimation of TR, with over half of those meeting 
criteria for clozapine not treated with it.  
We found notable clinical heterogeneity of course and outcome, with 34% of cases fulfilling 
the criteria for TR at 5 years, a relatively high rate, possibly reflecting the fact that a higher 
proportion were recruited from inpatient as opposed to community settings.  A higher 
proportion recruited from inpatient settings, might indicate a greater clinical need, than those 
who were managed in the community setting (though who weren’t recruited to this study). 
However, we did not identify a greater illness severity as measured by total PANSS scores 
in those recruited from an inpatient setting compared to those recruited from a community 
setting. Nonetheless, the increased proportion of cases that were inpatients at the time of 
recruitment, and the recruitment from clinical services rather than by population screening or 
other methods may mean that the rate of TRS identified is an overestimate. We were unable 
to directly assess neurodevelopmental risk factors, (excepting a lack of difference in IQ and 
premorbid IQ between the TR and non TR groups), which one might postulate would be 
increased in those with a higher risk of TR relating to a younger age of onset. 
Conclusions 
The findings from this study indicate that an early contact for psychosis during the ages of 
18-20, particularly in males is a strong predictor of TRS. Seventy percent of the TR subgroup 
presented with a treatment resistant picture at first contact, with no symptom remission 
occurring over the first six months of treatment. We did not find evidence suggesting that 
social factors and premorbid functioning were associated with the emergence of TR during 
the course of illness. Our findings reinforce the case for early assessment of treatment 
resistance in first episode patients so that clozapine may be considered and introduced 
promptly as a third line treatment in first episode schizophrenia. Future studies with larger 
samples are required to replicate and progress this important area of clinical prediction.  
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